Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: Pharmacogenet Genomics. 2011 Jul;21(7):403–416. doi: 10.1097/FPC.0b013e328346e8c0

Figure 2.

Figure 2

CYP2A6 diplotype/ phenotype association among normal metabolizer alleles, CYP2A6*1B,*1D,*1H, and *14. Time 1 (t1) =30 min. The boxplot provides a summary of the data distribution. The box represents the interquartile range, which includes 50% of values. The line across the box indicates the median. The whisker lines extend to the highest and lowest values that are within 1.5x the interquartile range. Further outliers are marked with circles. N = CYP2A6 normal metabolizer haplotypes (*1B,*1D,*1H,*14); *1A = CYP2A6*1A(51A);*9 = CYP2A6*9; L = CYP2A6 putative loss-of-function haplotypes (*2, *4, *12). The N/N (n=95) group is significantly greater than the N/*1A (n=33, p=0.0001), N/*9 (n=20, p=6.1×10−5), and *1A/*1A (n=8, p=0.008) groups. The L/N (n=17) group is significantly greater than the L/*1A group (n=4, p=0.0002).